Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Key Highlights
- ➤Aprea to host October 20 virtual panel on WEE1 inhibition in precision oncology
- ➤Panel will examine WEE1 biology, selectivity challenges, and upcoming scientific developments
- ➤APR-1051 is being evaluated in Phase 1 ACESOT-1051 for advanced solid tumors
- ➤Aprea’s clinical programs include APR-1051 and ATRN-119 for solid tumor indications
Expert Statements
Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute, Chief Scientific Officer of NEXT Oncology, and Clinical Assistant Professor at Johns Hopkins School of Medicine
“”
Kevin DeGeeter, Managing Director in equity research at Ladenburg Thalmann & Co. Inc.
“”
Eugene Kennedy, Chief Medical Advisor of Aprea Therapeutics, Inc.
“”
DOYLESTOWN, Pa., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that it will host a virtual panel discussion, "The State of WEE1 Inhibition in Precision Oncology," on Tuesday, October 20, 2026, at 11 am ET.
Disrupting the DNA damage response has become a compelling therapeutic strategy in oncology in recent years and WEE1 inhibitors are among the most promising drugs being developed within this class. Ahead of the European Society for Medical Oncology (ESMO) Congress 2026, this panel will cover the underlying biology of WEE1, the selectivity challenge that has shaped the class, and what to watch in the months ahead, across scientific, clinical, and market perspectives.
Get started
Create a free account to read the full story.